



THE AD HOC GROUP FOR MEDICAL RESEARCH

The Ad Hoc Group Fiscal Year 2027 Recommendation

CIRCULATING FOR ENDORSEMENTS

The [INSERT # OF SIGNATORIES] undersigned members of the Ad Hoc Group for Medical Research, which includes organizations representing patients, scientists, health professionals, research and academic institutions, educators, and industry, recommends at least \$51.303 billion for the National Institutes of Health (NIH) for fiscal year (FY) 2027, which would represent a \$4.087 billion or 8.7% increase over the enacted funding level for NIH in FY 2026.

Our community is deeply grateful for the longstanding bipartisan support for NIH, including the federal investment in FY 2026. Robust support for medical research makes Americans healthier. Patients across the country -- from urban centers to rural communities -- benefit from medical research supported by the NIH, which serves as the foundation for nearly every preventive intervention, diagnostic, treatment, and cure in practice today. Each year, more than 300,000 researchers across labs and other settings in nearly every congressional district nationwide^{i,ii} conduct research on the most promising ideas to overcome existing and emerging health threats. This research leads to medical breakthroughs that deliver proven benefits for patients, including advances in the prevention and treatment of cancer, Alzheimer's disease and related dementias, diabetes, Parkinson's disease, chronic conditions, autoimmune diseases, and many other diagnoses affecting children, adults, seniors, families, and communities every day, robbing them of their potential.

Our community is committed to advancing the highest quality science that earns the public's confidence and to ensuring strong research capacity across a wide array of settings and communities. Optimizing this work requires sustained, reliable growth in NIH funding; a fully staffed agency; and ensuring any potential policy changes do not result in dramatic decreases in funded proposals. The federal investment in NIH fosters collaboration among institutions across states, maximizing the reach of each taxpayer dollar to respond effectively to public health needs and leveraging talent nationwide in ways that could be limited if states or industry alone drove decision-making.

Beyond the direct health benefits to patients, federal investment in medical research has a powerful multiplier effect: it stimulates local and regional economies, spurs new industries, strengthens the United States' global competitiveness, supports national security, creates viable career paths for the next generation of scientists, and generates additional high-quality jobs in communities across the country. While U.S. investment faces uncertainty, China and other global competitors are expanding incentives for domestic biomedical innovation to strengthen their competitive advantage.ⁱⁱⁱ To avoid shifting the scientific, economic, and commercial returns of new discoveries and treatments overseas, we must resume a trajectory of strong growth in NIH funding.

We urge lawmakers to continue to support patients, discovery, and economic growth, to ensure a funding allocation for the Labor-HHS Subcommittee that allows for the necessary

investment in NIH and other agencies that promotes the health of all Americans, and to work expeditiously to complete FY 2027 appropriations in a timely manner. The health of our nation and our national security are at stake.

of Signatories as of DATE

The Ad Hoc Group for Medical Research is a coalition of over 500 patient and voluntary health groups, medical and scientific societies, academic and research organizations, and industry. The Ad Hoc Group has one mission: to enhance the federal investment in biomedical, behavioral, social, and population-based research by increasing the funding for the National Institutes of Health.

ⁱ National Institutes of Health. Impact of NIH Research; Direct Economic Contributions.

<https://www.nih.gov/about-nih/what-we-do/impact-nih-research/serving-society/direct-economic-contributions>. Accessed February 4, 2026.

ⁱⁱ Federation of American Societies for Experimental Biology. Federal Research Funding Data.

<https://www.faseb.org/science-policy-and-advocacy/federal-funding-data>.

Accessed February 4, 2026.

ⁱⁱⁱ National Security Commission of Emerging Biotechnology. The Future of U.S.–China Biotechnology Competition

<https://www.biotech.senate.gov/wp-content/uploads/2025/12/NSCEB-Future-of-U.S.-China-Biotech-Competition-Dec-2025.pdf>. Accessed February 4, 2026.